fda removing semaglutide ends shortage, closing the door on compounded Wegovy, Ozempic FDA moves to remove GLP-1

Compared with non-GLP-1RA anti-diabetes medications, semaglutide was associated with a significantly lower risk of incident CUD, though the association attenuated over time

[The supplementation of L-carnitine does not promote alterations in the resting metabolic rate and in the use of energetic substrates in physically active individuals]

Efficient gene delivery vectors by tuning the surface charge density of amino acid-functionalized gold nanoparticles

Mel and GSH were administered intraperitoneally for 7 days before CARB injection

Insights into the allosteric mechanism of setmelanotide (RM-493) as a potent and first-in-class melanocortin-4 receptor (MC4R) agonist to treat rare genetic disorders of obesity through an in silico approach

Company Profiles: Coverage of players such as AbbVie Inc., AstraZeneca, Bachem Holding AG, Biocon Limited, Boehringer Ingelheim International GmbH and more